A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

by lowes1 on September 27, 2013

Condition:   Unresectable Non-Small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Lurbinectedin (PM01183)
Sponsors:   PharmaMar;   PharmaMar
Not yet recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: